Aviva Systems Biology

Aviva Systems Biology

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Aviva Systems Biology is a established, revenue-generating provider of essential research reagents for the global life science market. Its core business revolves around a large catalog of antibodies, ELISA kits, and recombinant proteins, supplemented by custom service offerings like its 'Protein on Demand™' platform. The company serves a wide range of research areas from cancer and neuroscience to immunology and infectious disease, positioning itself as a one-stop shop for academic, biotech, and pharmaceutical researchers. Its operational focus is on product breadth, validation, and custom solutions rather than therapeutic or diagnostic development.

Antibodies

Technology Platform

Integrated reagent development platform specializing in antibody generation (monoclonal, polyclonal, recombinant), recombinant protein expression (Protein on Demand™), and ELISA kit development and validation.

Opportunities

Growth is driven by expanding global biomedical R&D, particularly in neuroscience and oncology, and the increasing demand for validated reagents to address research reproducibility.
Geographic expansion into high-growth markets like China presents a significant opportunity.

Risk Factors

The company faces intense competition from large conglomerates and niche players in the reagent market.
It is also vulnerable to fluctuations in research funding and potential technological disruption from newer, non-antibody-based proteomic platforms.

Competitive Landscape

Aviva competes in the crowded life science reagents market against giants like Thermo Fisher, Abcam, and Bio-Techne, as well as numerous specialized antibody producers. It differentiates through its large catalog of validated ELISA kits, custom service flexibility, and focus on recombinant antibody technology.